Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stem cells bank established in Romania

This article was originally published in Scrip

Executive Summary

Greece's Stem-Health and Centrul Medical Unirea, a Romanian company, have founded Stem-Health Unirea, with an estimated investment of €800,000. The two founding firms will have 50% stakes in the new company. It will be located on Unirea's site in Bucharest and should start operating in full early next year. Stem-Health, which is a 50%-owned subsidiary of Hygeia, , was established last year to develop a network of stem cell banks in Greece and countries of south-eastern Europe and the Middle East. Stem-Health Unirea is Hygeia's second stem cell bank. The first one was Stem-Health Hellas in Greece, which will now help Stem-Health Unirea with know-how and staff training. Both stem cell banks use protocols and procedures for collecting and processing cord blood and storing stem cells developed by the New England cord blood bank.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC026552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel